Beyond breast and ovarian cancer, prostate and pancreatic cancer also have targetable homologous recombination deficiency (HRD) beyond the well-known BRCA1 and BRCA2 with relevance that exceeds diagnostic purposes. This evidence concerns the gene BRCA2 and hypoparathyroidism-retardation-dysmorphism syndrome.